News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Abbott Laboratories (ABT) Says Breakup Plans on Target as Profit Tops Estimates



4/18/2012 7:17:58 AM

Abbott Laboratories (ABT), splitting into a drugmaker and a diversified health-care business, reported net income that beat analysts’ estimates and raised its 2012 forecast as sales jumped more than expected for its top product.

First-quarter revenue climbed 4.6 percent to $9.46 billion in the quarter, the Abbott Park, Illinois-based company said in a statement today. Humira, an autoimmune drug, gained about 17 percent to $1.93 billion, beating the $1.85 billion average of four analyst estimates compiled by Bloomberg.

Read at Bloomberg
Read at Reuters
Read at Wall Street Journal
Read at RTT News


comments powered by Disqus
Abbott
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES